查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球預防性疫苗市場
市場調查報告書
商品編碼
1176602

2023-2030 年全球預防性疫苗市場

Global Preventive Vaccine Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

在預測期內 (2023-2030)，預防疫苗的市場規模預計將以 5.3% 的複合年增長率增長。

預防性疫苗是一種生物製品，可刺激針對特定病原體的免疫力。 疫苗通常含有類似於引起疾病的生物體的物質，通常由生物體或毒素的死亡或減毒版本製成。

市場動態

推動全球預防性疫苗市場發展的主要因素是世界上疾病數量的增加、研發支出的增加以及公眾對預防性疫苗的認識。 新產品發布的增加促進了預防性疫苗市場的增長。

增加研發投資和增加新產品發布預計將推動市場增長。

越來越多地採用這些預防和治療麻疹、白喉、脊髓灰質炎、風疹和流感等多種疾病的預防性疫苗產品，促進了預防性疫苗市場的增長。它是推動力。 此外，世界上越來越多的疾病也在推動市場的增長。 許多醫療保健公司正在加緊研發活動以開發新產品。

預防性疫苗用於預防或預防疾病在兒童和成人中的傳播。 由於各種疾病的增加，這些疫苗的市場正在全球範圍內擴大。 此外，主要參與者對新型疫苗和技術先進產品的研究和開發不斷增加，預計也將在市場增長中發揮重要作用。

各種新產品的發布、監管批准和研究正在推動市場增長。 例如，2022 年 4 月 11 日，田邊三菱製藥公司宣布 BIKEN（大阪大學微生物病研究組）聯合開發了白喉、百日咳預防、破傷風、b 型流感嗜血桿菌（Hib）和急性骨髓炎（已宣布它已向厚生勞動省申請脊髓灰質炎聯合疫苗的上市許可）。 根據國家免疫規劃，針對這五種疾病的聯合疫苗被選為2014年指定的高優先級疫苗。

預計預防性疫苗的副作用會阻礙市場的增長。

然而，與不同類型疫苗相關的各種輕微副作用可能會阻礙市場增長。 接種 DTaP 疫苗後可能會出現發燒、注射部位腫脹和疼痛、煩躁、疲勞、嘔吐和食慾不振。 接種流感疫苗後，注射部位可能會出現紅腫、肌肉疼痛、頭痛和發燒等症狀。

流感疫苗接種後可能會出現鼻塞、流鼻涕、頭痛和氣喘。 MMR 疫苗接種後可能會出現臉頰和頸部腫脹、關節僵硬和暫時性疼痛（主要發生在成人和少女身上）。 接種輪狀病毒疫苗後，可能會出現煩躁、嘔吐和暫時性輕度腹瀉。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了積極影響。 COVID-19 的爆發嚴重影響了醫療保健行業。 由於 COVID 疫苗的各種研究和臨床試驗已經認真開始，預防性疫苗市場因 COVID 而獲得了巨大收益。 迫切需要一種疫苗來防止 COVID 及其變體在全球傳播。 世界各地正在發生各種舉措、產品發布、創新、合作和合併，推動了市場的增長。 例如，2022 年 11 月 10 日，賽諾菲和葛蘭素史克宣布，他們共同開發的下一代 COVID-19 加強疫苗 VidPrevtyn Beta 獲得歐盟委員會批准，用於 18 歲及以上成年人的 COVID-19 預防。宣布。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 增加研發投資
      • 新產品發布激增
      • 疾病發病率增加
    • 約束因素
      • 疫苗的不良反應
    • 商機
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 定價分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按疫苗類型分類

  • 減毒疫苗
  • 滅活□□疫苗
  • 亞基、重組、綴合物、多醣疫苗
  • mRNA疫苗
  • 類毒素疫苗
  • 病毒載體疫苗

第8章給藥途徑

  • 口語
  • 皮下給藥
  • 其他

第9章疾病適應症

  • 肺炎球菌疾病
  • 水痘
  • 人乳頭瘤病毒
  • 流感
  • 腦膜炎球菌感染
  • MMR（麻疹、腮腺炎、風疹）
  • 小兒麻痺症
  • 肝炎
  • 登革熱
  • DPT（白喉、百日咳、破傷風）
  • 輪狀病毒
  • 黃熱病
  • 傷寒
  • 其他

第 10 章最終用戶

  • 成人
  • 兒科

第11章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第12章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第13章公司簡介

  • 阿斯利康
    • 公司概況
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Astellas Pharma, Inc.
  • Pfizer, Inc
  • Johnson & Johnson
  • GSK plc
  • Merck & Co., Inc.
  • Sanofi
  • Bavarian Nordic
  • Emergent Biosolutions
  • Mitsubishi Tanabe Pharma Corporation

第14章 DataM

簡介目錄
Product Code: DMBT43

Market Overview

Preventive Vaccine Market size was valued at US$ XX million in 2023 and is estimated to reach US$ XX million by 2030, growing at a CAGR of 5.3% during the forecast period (2023-2030).

A preventive vaccine is a kind of biological preparation which stimulates immunity to a specific pathogen. A vaccine commonly contains an agent similar to the disease-causing microbe and is usually made from killed or weakened forms of the microorganism or its toxins.

Market Dynamics

The major factors driving the global preventive vaccine market are an increase in the number of diseases globally, rising research and development expenditure and awareness among the population regarding these preventive vaccines. An increase in novel product launches contributes to the growth of the preventive vaccine market.

The increasing investment in R&D and rising novel product launches are expected to drive the market's growth.

The rising adoption of these preventive vaccine products for the prevention or treatment of various diseases, such as measles, diphtheria, polio, rubella, influenza and many more and the rising number of novel product launches drive the preventive vaccine market. An increase in diseases globally is also aiding the market growth. There has been an increase in R&D activities by many healthcare companies to develop novel products.

The preventive vaccine is used for the prevention of diseases and the spreading of these diseases in children and adults. The market for these vaccines is increasing worldwide due to the increasing number of different diseases. Moreover, the increase in research and development of novel vaccines and the availability of technologically advanced products by key players are also expected to play a vital role in the market's growth.

Various novel product launches, regulatory approvals and research studies contribute to the market's growth. For instance, in April 11, 2022, Mitsubishi Tanabe Pharma Corporation announced that BIKEN (The Research Foundation for Microbial Diseases of Osaka University) submitted the application to the Ministry of Health, Labour and Welfare for their jointly developed combination vaccine marketing authorization for diphtheria, prophylaxis of pertussis, tetanus, Haemophilus influenzae type b (Hib) and acute poliomyelitis (polio). According to the "National Immunization Plan," this combination vaccine utilized for five diseases has been chosen as the vaccine with high development priority specified in 2014.

The side effects associated with preventive vaccines are expected to hamper the market's growth.

However, various minor side effects associated with different types of vaccines may hinder the market's growth. Fever, swelling or soreness where the shot was given, fussiness, tiredness, vomiting and loss of appetite can occur after DTaP vaccination. Redness or swelling happens where the shot is given, and muscle aches, headaches and fever can happen after influenza vaccination.

After influenza vaccination, nasal congestion, runny nose, headache and wheezing can happen. In the cheeks or neck, swelling of the glands or stiffness and temporary pain in the joints (mostly in adults or teenage women) sometimes happen after MMR vaccination. Irritability, vomiting, or temporary, mild diarrhea, can occur after the rotavirus vaccine.

COVID-19 Impact Analysis

The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The preventive vaccine market has experienced huge profits due to COVID, as various research and clinical trials got started in full swing for COVID vaccine. An urgent need for vaccines to prevent the spreading of COVID and its variant across the globe. Various initiatives, product launches, innovations, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in November 10, 2022, Sanofi and GSK announced the approval of their jointly developed VidPrevtyn Beta, the next-generation COVID-19 booster vaccine, by the European Commission for COVID-19 prevention in adults aged 18 years and older.

Segment Analysis

The live-attenuated vaccines segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The live-attenuated vaccines segment is the highest market holder in the global preventive vaccine market. The global preventive vaccine market is segmented based on vaccine type: live-attenuated vaccines, inactivated vaccines, subunit, recombinant, conjugate, and polysaccharide vaccines, mRNA vaccines, toxoid vaccines and viral vector vaccines. The live-attenuated vaccines segment is the largest market shareholder due to its better efficacy and results, increasing diseases and rising adoption of these preventive vaccines.

The live-attenuated vaccines utilize an attenuated or weakened form of the microbe that causes a disease. As these vaccines are like the natural infection they help avert, they provide a long-lasting and strong immune response. Most of the live vaccines, in just 1 or 2 doses, can provide a lifetime of protection contrary to the microbe and the disease caused by it. These vaccines are used for the protection against smallpox, rotavirus, yellow fever, chickenpox and combined vaccine of measles, mumps, and rubella (MMR).

The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market's growth. For instance, in February 24, 2022, Mitsubishi Tanabe Pharma Corporation announced that GlaxoSmithKline plc and Medicago Inc., its affiliated company, jointly announced receiving full approval for COVIFENZ (COVID-19 vaccine) from Health Canada. COVIFENZ is a virus-like particle vaccine that is administered with the pandemic adjuvant of GSK indicated for COVID-19 prevention.

Geographical Analysis

North America holds the largest market share in the global preventive vaccine market.

North America dominates the global preventive vaccine market, primarily due to its large population, excellent medical infrastructure, and rising number of diseases. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market's significant size is attributed to the high medical expenditure.

Increasing expenditure on healthcare and raising awareness among people is also contributing to the market's growth in this region. Advancement of types of vaccines for prevention of different disease indications such as pneumococcal disease, varicella, human papillomavirus, influenza, meningococcal disease, MMR (measles, mumps, rubella), polio, hepatitis, dengue, DPT (diphtheria, pertussis, and tetanus), rotavirus, yellow fever, typhoid fever and more, increase in pharmaceutical establishment across the region and government approvals and the presence of key players in the region are contributing to the growth of the preventive vaccine market.

Moreover, the growing number of product launches is responsible for the market's growth. Many key developments, regulatory approvals, technological advancements, collaborations, and agreements are taking place in this region. For instance, in October 10, 2022, GSK plc announced approval for its BOOSTRIX (Reduced Diphtheria Toxoid, Tetanus Toxoid and Acellular Pertussis Vaccine) by the US Food and Drug Administration (FDA) for immunization during the pregnancy to prevent pertussis (whooping cough) in infants.

Competitive Landscape

The preventive vaccine market is moderately competitive with local and global companies' presence. AstraZeneca, Astellas Pharma Inc., Pfizer, Inc, Johnson & Johnson, GSK plc, Merck & Co., Inc., Sanofi, Bavarian Nordic, Emergent Biosolutions, Mitsubishi Tanabe Pharma Corporation and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in August 16, 2022, GSK plc announced its completion of the acquisition of Affinivax Inc, a Cambridge-based clinical-stage biopharmaceutical company. Affinivax has initiated a novel class of vaccine development. The most advanced of them are next-generation pneumococcal vaccines.

GSK PLC.

Overview: GlaxoSmith Kline is a company that develops and provides vaccines, medicines and several consumer healthcare-related products. Its products impact the health of humans on a large scale.

Product Portfolio:

VidPrevtyn Beta: It is the next-generation COVID-19 booster vaccine developed for COVID-19 prevention in adults aged 18 years and older and approved by the European Commission.

Key Developments: In February 3, 2021, GlaxoSmithKline plc and CureVac N.V. announced a novel collaboration of €150M for the joint development of next-generation mRNA vaccines for preventing COVID-19 virus with the capability for a multi-valent approach to deal with multiple emerging variants with one vaccine.

The global preventive vaccine market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in investment in research and development
      • 4.1.1.2. Surge in novel product launches
      • 4.1.1.3. Increasing incidence of diseases
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with vaccines
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1 Porter's Five Forces Analysis
  • 5.2 Supply Chain Analysis
  • 5.3 Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Vaccine Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 7.1.2. Market Attractiveness Index, By Vaccine Type
  • 7.2. Live-attenuated vaccines*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Inactivated vaccines
  • 7.4. Subunit, recombinant, conjugate, and polysaccharide vaccines
  • 7.5. mRNA vaccines
  • 7.6. Toxoid vaccines
  • 7.7. Viral vector vaccines

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Subcutaneous
  • 8.4. Other

9. By Disease Indication

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 9.1.2. Market Attractiveness Index, By Disease Indication
  • 9.2. Pneumococcal Disease *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Varicella
  • 9.4. Human Papilloma Virus
  • 9.5. Influenza
  • 9.6. Meningococcal Disease
  • 9.7. MMR (Measles, Mumps, Rubella)
  • 9.8. Polio
  • 9.9. Hepatitis
  • 9.10. Dengue
  • 9.11. DPT (diphtheria, pertussis, and tetanus)
  • 9.12. Rotavirus
  • 9.13. Yellow Fever
  • 9.14. Typhoid Fever
  • 9.15. Others

10. By End-User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.1.2. Market Attractiveness Index, By End-User
  • 10.2. Adults *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Pediatrics

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Indication
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Products Benchmarking
  • 12.4. List of Key Companies to Watch

13. Company Profiles

  • 13.1. AstraZeneca *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Astellas Pharma, Inc.
  • 13.3. Pfizer, Inc
  • 13.4. Johnson & Johnson
  • 13.5. GSK plc
  • 13.6. Merck & Co., Inc.
  • 13.7. Sanofi
  • 13.8. Bavarian Nordic
  • 13.9. Emergent Biosolutions
  • 13.10. Mitsubishi Tanabe Pharma Corporation

LIST NOT EXHAUSTIVE

14. Global Preventive Vaccine Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and End-User
  • 14.3. Contact Us